New Epinephrine Injection Launched in Retail Pharmacies
Sandoz’ 0.3 mg and 0.15 mg injections are indicated for the emergency treatment of allergic reactions including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
The retail launch of Sandoz’ epinephrine (Symjepi) 0.3 mg and 0.15 mg injections was announced today. The launch makes adult and pediatric doses immediately available in local pharmacies across the United States.
Granted FDA approval in 2018, both doses of this product were made available in hospitals and clinics earlier this year.
Sandoz’ 0.3 mg and 0.15 mg injections are indicated for the emergency treatment of allergic reactions including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
“Our collaboration with retail partners will enable patients and their caregivers to conveniently access Symjepi, a cost-effective treatment option with a compact and user-friendly design,” said Carol Lynch, President of Sandoz Inc, a division of Novartis, in a prepared statement.
The 0.3 mg and 0.15 mg injections are intended for immediate administration in patients who weigh approximately 66 pounds or more, and who weigh between 33 and 65 pounds, respectively, who are determined to be at an increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. These epinephrine products are small, single-dose, pre-filled syringes and device combinations that provide an alternative to epinephrine auto-injectors.
Ongoing
from several drug manufacturers
have been highlighted by the FDA. Health care providers should
prescribe “epinephrine injection” rather than “epinephrine auto-injector” to ensure
pharmacies provide epinephrine medicine alternatives during their first attempt to fill their prescription, according to Sandoz.
shortages of epinephrine auto-injectors
RELATED ARTICLES
- Generic Epinephrine Auto-Injector Available to Hospitals, Clinics
- FDA Grants Fast Track Designation to Epinephrine Nasal Spray
Reference
Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine [news release]. Princeton, NJ; July 9, 2019: Sandoz website. https://www.us.sandoz.com/news/media-releases/sandoz-extends-symjepi-epinephrine-injection-launch-us-pharmacies-help-improve. Accessed July 9, 2019.
